Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Supernus Pharm
(NQ:
SUPN
)
34.58
+0.33 (+0.95%)
Streaming Delayed Price
Updated: 2:20 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Supernus Pharm
< Previous
1
2
Next >
Supernus Announces Second Quarter 2024 Financial Results
August 06, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
August 01, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
July 23, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
May 23, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
May 09, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces First Quarter 2024 Financial Results
May 08, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
May 02, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
May 01, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
May 01, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
April 29, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
April 24, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Provides Regulatory Update for SPN-830
April 08, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in Two Upcoming Investor Conferences
March 06, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
February 28, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
February 13, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
February 05, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Third Quarter 2023 Financial Results
November 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the Jefferies London Healthcare Conference
November 07, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
November 02, 2023
PDUFA Target Action Date of April 5, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
October 25, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
October 16, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
October 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
September 27, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
September 09, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the Wells Fargo Healthcare Conference
August 31, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Bethany L. Sensenig Joins Supernus’ Board of Directors
August 21, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Second Quarter 2023 Financial Results
August 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023
July 24, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.